Saturday, December 5, 2020

ZIOPHARM Oncology Inc. [ZIOP] moved down -8.54: Why It’s Important

Must read

Death Toll In U.S. Could Reached 321,000 In A Month, Air Traveling Rose 22% This Week

In recent weeks, the outbreak of coronavirus has led to new travel restriction initiatives in a number of U.S. states and cities, including California,...

Luminar Technologies (LAZR) Stock Debut With 27% Rise, Zscaler (ZS) Stock Also Rose 26%

Shares of Luminar Technologies Inc (LAZR) increased by more than 27% to $22.98 after it started trading as a public company on Thursday. The...

U.S. Indices Started December With A Record Breaking Day

Wall Street began December on the right foot after gains of 11 percent to 12 percent for its key indices in November, with the...

UK Promised Vaccination In Next Week, U.S. To Approve New Support Package

The arrangements for coronavirus vaccine programs are well underway on the health front. On Tuesday, the UK distinguished itself by being the first country...

ZIOPHARM Oncology Inc. [NASDAQ: ZIOP] slipped around -0.28 points on Thursday, while shares priced at $3.00 at the close of the session, down -8.54%. ZIOPHARM Oncology Inc. stock is now -36.44% down from its year-to-date (YTD) trading value. ZIOP Stock saw the intraday high of $3.21 and lowest of $3.00 per share. The company’s 52-week high price is 7.25, which means current price is +67.13% above from all time high which was touched on 01/16/20.

Compared to the average trading volume of 1.86M shares, ZIOP reached a trading volume of 2311144 in the most recent trading day, which is why market watchdogs consider the stock to be active.


My #1 Stock Trade This Year (HINT: It's a COVID-19 Play)

Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.    

>> Sign Up Now to Get Name & Ticker Symbol of Next Triple-Digit Gainer <<

Sponsored


What do top market gurus say about ZIOPHARM Oncology Inc. [ZIOP]?

Cantor Fitzgerald have made an estimate for ZIOPHARM Oncology Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 04, 2020. The new note on the price target was released on August 23, 2019, representing the official price target for ZIOPHARM Oncology Inc. stock. Previously, the target price had yet another raise to $7, while Lake Street analysts kept a Buy rating on ZIOP stock.

The Average True Range (ATR) for ZIOPHARM Oncology Inc. is set at 0.25 The Price to Book ratio for the last quarter was 3.33, with the Price to Cash per share for the same quarter was set at 0.81.

How has ZIOP stock performed recently?

ZIOPHARM Oncology Inc. [ZIOP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.64. With this latest performance, ZIOP shares gained by 0.33% in over the last four-week period, additionally sinking by -40.94% over the last 6 months – not to mention a drop of -38.65% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZIOP stock in for the last two-week period is set at 48.81, with the RSI for the last a single of trading hit 46.36, and the three-weeks RSI is set at 50.16 for ZIOPHARM Oncology Inc. [ZIOP]. The present Moving Average for the last 50 days of trading for this stock 2.87, while it was recorded at 3.16 for the last single week of trading, and 3.81 for the last 200 days.

ZIOPHARM Oncology Inc. [ZIOP]: Deeper insight into the fundamentals

Return on Total Capital for ZIOP is now -63.26, given the latest momentum, and Return on Invested Capital for the company is -129.34. Return on Equity for this stock declined to -130.47, with Return on Assets sitting at -115.39. When it comes to the capital structure of this company, ZIOPHARM Oncology Inc. [ZIOP] has a Total Debt to Total Equity ratio set at 2.48. Additionally, ZIOP Total Debt to Total Capital is recorded at 2.42, with Total Debt to Total Assets ending up at 2.16. Long-Term Debt to Equity for the company is recorded at 1.66, with the Long-Term Debt to Total Capital now at 1.62.

Reflecting on the efficiency of the workforce at the company, ZIOPHARM Oncology Inc. [ZIOP] managed to generate an average of -$1,613,644 per employee.ZIOPHARM Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.60 and a Current Ratio set at 11.60.

Earnings analysis for ZIOPHARM Oncology Inc. [ZIOP]

With the latest financial reports released by the company, ZIOPHARM Oncology Inc. posted -0.09/share EPS, while the average EPS was predicted by analysts to be reported at -0.08/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -12.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZIOP.

Insider trade positions for ZIOPHARM Oncology Inc. [ZIOP]

There are presently around $325 million, or 53.30% of ZIOP stock, in the hands of institutional investors. The top three institutional holders of ZIOP stocks are: VANGUARD GROUP INC with ownership of 15,156,323, which is approximately 20.336% of the company’s market cap and around 1.50% of the total institutional ownership; MSD PARTNERS, L.P., holding 15,151,516 shares of the stock with an approximate value of $49.7 million in ZIOP stocks shares; and BLACKROCK INC., currently with $45.74 million in ZIOP stock with ownership of nearly 11.634% of the company’s market capitalization.

Positions in ZIOPHARM Oncology Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 78 institutional holders increased their position in ZIOPHARM Oncology Inc. [NASDAQ:ZIOP] by around 17,548,284 shares. Additionally, 60 investors decreased positions by around 4,268,321 shares, while 34 investors held positions by with 77,150,545 shares. The mentioned changes placed institutional holdings at 98,967,150 shares, according to the latest SEC report filing. ZIOP stock had 24 new institutional investments in for a total of 4,592,983 shares, while 27 institutional investors sold positions of 728,588 shares during the same period.

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Luminar Technologies (LAZR) Stock Debut With 27% Rise, Zscaler (ZS) Stock Also Rose 26%

Shares of Luminar Technologies Inc (LAZR) increased by more than 27% to $22.98 after it started trading as a public company on Thursday. The...

UK Promised Vaccination In Next Week, U.S. To Approve New Support Package

The arrangements for coronavirus vaccine programs are well underway on the health front. On Tuesday, the UK distinguished itself by being the first country...

U.S. Indices Started December With A Record Breaking Day

Wall Street began December on the right foot after gains of 11 percent to 12 percent for its key indices in November, with the...

Oil Futures Saw Below 1% Decline, OPEC Still To Decide Upon Production Cuts

On Monday, November 30, after a rise of 1.1 percent during Friday trading, price of oil futures declined -0.4 percent to $45.34 per barrel...

Death Toll In U.S. Could Reached 321,000 In A Month, Air Traveling Rose 22% This Week

In recent weeks, the outbreak of coronavirus has led to new travel restriction initiatives in a number of U.S. states and cities, including California,...

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the DBTNews.com pre-market morning brief 100% free

We do not sell or share your information with anyone.